I know they’ve got Casgevy out there now, but it sounds like the rollout’s been kinda slow, top put it mildly. I'm curious if the complexity of the treatment is what’s holding it back or if it’s just early days. I’m not sure what to make of it yet. No profits, tough market, but also barely any competition. Could be one of those “wait and see” plays.
There are no replies in this thread yet. Be the first to post a reply below: